SS-31

SS-31 is a mitochondria-targeted peptide that people run primarily for mitochondrial health and anti-aging, with interest centered on its role in reducing oxidative stress and supporting cardiac and renal function. Clinician protocols typically call for 100 mcg to 1 mg subcutaneous injection daily in the morning, cycled over 8–12 weeks. The clinical picture is incomplete: SS-31 has trials across a wide range of exploratory indications, but most have not posted results, leaving the off-label case resting on small early-phase human data rather than robust evidence.

SS-31

Research Evidence

Evidence shape

SS-31 has reached Phase 3 and logged 28 registered trials across conditions ranging from reperfusion injury to heart failure to rare mitochondrial diseases — but only reperfusion injury has posted quantitative results. Eight blinded trials from two sponsors are on record, with nine linked publications across the registered trial set. The remaining 20 indications are almost entirely exploratory: 15 are single-trial entries with no outcomes data filed.

Depthhow much
28 registered trials
21 completed · 10 with posted results · 3 recruiting / active · combined n=584
Breadthhow many areas
21 indications mapped
1 with results · 18 thin / exploratory · 1 animal-only · 15 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
8 blinded with results · 2 distinct sponsors · AE rows aggregated from 6 trials · 9 linked publications on registered trials
Breadth and depth52 rows captured
Human
direct clinical signal
28
Animal
translational support
12
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
Nextgenpeps
US
10 mg
$0.79
$0.079/mg
2
High Purity Peptides
HK
500 mg
$250.00
$0.5/mg
3
Profound Aminos
--
40 mg
$49.00
$1.23/mg
4
Puratek Peptides
--
30 mg
$44.95
$1.5/mg
5
S1Research
--
50 mg
$94.00
$1.88/mg
6
Peptide Titans
US
100 mg
$209.99
$2.1/mg

price offers can be sorted by column

1-6 of 83

Dosing & Protocol

How SS-31 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 14
Typical dose
250 µg10 µg – 250 µg
25 µg
125 µg
1 mg
8 mg
50 mg
Frequency
daily
Timing
unspecified
Route
subQ
Cycle
unspecified

Across 14 completed trials, registry dosing was 10 µg–250 µg daily subQ.

8 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Starting dose
100 µg100 µg – 1 mg
25 µg
125 µg
1 mg
8 mg
50 mg
Frequency
daily
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 100 µg–1 mg daily subQ (1 source).

1 source
Anecdotal
Community-reported real-world use · n = 18
Typical dose
1 mg250 µg – 50 mg
typical
25 µg
125 µg
1 mg
8 mg
50 mg
distribution of 7 reported doses · darker = more reports
By reported cadence
Daily250 µg · n=1
2×/week50 mg · n=1
Schedule unstated1 mg (500 µg–2 mg) · n=3
Frequency
mixed
Timing
unspecified
Route
subQ
Cycle
unspecified

Reported doses span 250 µg–50 mg, most commonly 1 mg; schedules vary, most often daily.

5 sources

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Regulatory safety notes

Warnings and precautions
  • • Benzyl alcohol toxicity : Do not use in neonates.
Contraindications
  • • Serious hypersensitivity to elamipretide or any of the excipients in FORZINITY [see Warnings and Precautions (5.2) ]. Serious hypersensitivity to any of the ingredients (4 , 5.2)

Peptide feedback

0 forum replies

Live community discussion for SS-31, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.